Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Global Automated and Closed Cell Therapy Processing Systems Market Size, Share & Industry Analysis Report by Type, Scale, Workflow, Regional Outlook and Forecast, 2026-2033" has been added to ResearchAndMarkets.com's offering.
The global automated and closed cell therapy processing systems market is projected to reach USD 7.0 billion by 2033, expanding at a compound annual growth rate (CAGR) of 20.2% from 2026 to 2033. Market growth is being driven by accelerating investment in regenerative medicine, CAR-T cell therapies, stem cell therapies, personalized medicine, and advanced therapy medicinal products.
Healthcare organizations, biotechnology and pharmaceutical companies, contract development and manufacturing organizations, hospitals, and research institutions are increasingly adopting automated and closed cell therapy processing systems to improve manufacturing efficiency, scalability, safety, consistency, and regulatory compliance. The transition from manual, labor-intensive, and open processing methods toward integrated closed-system platforms is helping manufacturers reduce contamination risk, limit operator dependency, enhance reproducibility, and support progression from clinical development to commercial production.
Market Insights
- Non-stem cell therapy led the type segment with revenue of USD 943.2 million in 2025 and is forecast to reach USD 3.9 billion by 2033, registering a CAGR of 19.8%.
- Stem cell therapy is expected to record a CAGR of 20.7% from 2026 to 2033, supported by expanding regenerative medicine research and clinical development.
- Pre-commercial and R&D-scale applications generated USD 1.2 billion in 2025 and are projected to reach USD 5.0 billion by 2033, growing at a CAGR of 20.0%.
- Commercial-scale processing is forecast to expand at a CAGR of 20.6% as more cell therapies secure regulatory approval and enter large-scale manufacturing.
- Separation led the workflow segment with USD 507.9 million in 2025 and is expected to reach USD 2.0 billion by 2033, representing a CAGR of 19.2%.
- Other workflows are projected to register the fastest workflow CAGR of 21.5%, followed by fill-finish at 21.1% and cryopreservation at 21.0%.
- Apheresis is forecast to reach USD 1.3 billion by 2033, growing at a CAGR of 20.8% as patient- and donor-derived cell collection increases.
- North America led the market with USD 786.5 million in 2025 and is projected to reach USD 3.2 billion by 2033. LAMEA is expected to post the fastest regional CAGR of 21.6%.
Market Growth Drivers and Opportunities
Growth in the automated cell therapy manufacturing market is supported by expanding cell and gene therapy pipelines, increasing commercialization of CAR-T treatments, and rising demand for autologous and allogeneic therapies. Manufacturers are prioritizing closed processing, single-use technologies, process analytics, modular platforms, and digitally controlled production environments to improve throughput and maintain product quality.
Artificial intelligence and data-driven process analytics represent significant opportunities for predictive manufacturing optimization, real-time monitoring, and improved quality control. Modular automation platforms could also enable decentralized and point-of-care manufacturing by supporting flexible deployment across early-stage research, clinical production, and regional treatment centers.
Market adoption may be constrained by high capital and operating costs, complex validation requirements, stringent quality standards, and limitations in platform interoperability. Integrating multiple processing stages into a unified closed workflow also remains technically challenging, particularly when manufacturers handle diverse cell types, treatment formats, and production volumes.
Type, Scale, and Workflow Outlook
Non-stem cell therapy is expected to remain the leading type segment through 2033, supported by the development of CAR-T, T-cell receptor, natural killer cell, and other engineered cell therapies. These products require tightly controlled collection, isolation, activation, expansion, genetic modification, washing, concentration, and formulation processes. Stem cell therapy is also gaining momentum across regenerative medicine, tissue engineering, autoimmune disease research, neurological applications, orthopedic treatments, cardiovascular repair, and wound healing.
Pre-commercial and R&D-scale systems will continue to represent a substantial share of demand as academic institutions, biotechnology startups, and early-stage developers invest in flexible platforms for process development, clinical trial materials, protocol optimization, and small-batch production. Commercial-scale adoption is expected to accelerate as late-stage therapies advance toward approval and manufacturers require higher throughput, traceability, reproducibility, and GMP-compliant production.
Separation remains the leading workflow because cell therapy manufacturing requires reliable isolation of target cells from complex biological samples. Expansion systems are essential for producing clinically relevant cell volumes, while apheresis supports autologous and allogeneic collection. Automated fill-finish platforms improve aseptic processing and dosing consistency, and cryopreservation systems support storage, transportation, and treatment scheduling.
Regional Market Outlook
North America is expected to retain its market leadership through 2033, supported by substantial biopharmaceutical investment, advanced manufacturing infrastructure, high clinical trial activity, and continued commercialization of cell and gene therapies. Europe is projected to grow at a CAGR of 19.9%, benefiting from regenerative medicine research, established advanced therapy regulations, and expanding biomanufacturing capacity.
Asia Pacific is forecast to register a CAGR of 21.3% as China, Japan, India, South Korea, Singapore, and Australia increase biotechnology investment, clinical research, and healthcare infrastructure. LAMEA remains an emerging market but is expected to grow rapidly as investment in advanced therapeutics and automated cell processing expands across Latin America, the Middle East, and Africa.
Competitive Landscape
The automated and closed cell therapy processing systems market is moderately consolidated. Competition centers on end-to-end automation, single-use processing, digital integration, modularity, process analytics, regulatory compliance, and commercial scalability. Thermo Fisher Scientific Inc. holds a leading position through its broad cell processing, bioprocessing, analytical, and manufacturing portfolio. Cytiva, Sartorius AG, Miltenyi Biotec, and Lonza Group also maintain strong positions in automated processing and scalable cell therapy manufacturing.
Other notable participants include Fresenius Kabi, Terumo BCT, Bio-Techne, Cellares, and Merck KGaA. Recent industry activity includes the expansion of Cytiva's Sefia platform, Cellares' development of automated Smart Factories, Cytiva's collaboration with NecstGen, the partnership between MiLaboratories and Miltenyi Biotec, and the extension of Sartorius and Siemens' automation collaboration.
Companies Profiled
- Thermo Fisher Scientific Inc.
- Cytiva
- Sartorius AG
- Miltenyi Biotec B.V. & Co. KG
- Lonza Group AG
- Fresenius Kabi AG
- Terumo BCT, Inc.
- Bio-Techne Corporation
- Cellares Corporation
- Merck KGaA
Market Segmentation
- By Type: Non-stem cell therapy and stem cell therapy
- By Scale: Pre-commercial/R&D scale and commercial scale
- By Workflow: Separation, expansion, apheresis, fill-finish, cryopreservation, and other workflows
- By Geography: North America, Europe, Asia Pacific, and LAMEA
For more information about this report visit https://www.researchandmarkets.com/r/1c82fg
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
